Patrick Forde

Patrick has led the development of immunotherapy for surgically resectable lung cancer from initial concept to worldwide use, initially exploring the role of single agent anti-PD-1 as neoadjuvant therapy and later as principal investigator of the CheckMate 816 trial which led to the approval internationally of neoadjuvant chemo-immunotherapy for stage II-III lung cancer. Long term follow up from this study showed that just 3 doses of immunotherapy before surgery significantly improved long term survival for patients with lung cancer. He leads several translational efforts to optimize the treatment of lung cancer including the global platform neoadjuvant immunotherapy trial, NeoCOAST-2, exploring novel immunotherapy combinations prior to surgery for lung cancer.